Douglas Dolnak

866 total citations
6 papers, 638 citations indexed

About

Douglas Dolnak is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Epidemiology. According to data from OpenAlex, Douglas Dolnak has authored 6 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pharmacology, 2 papers in Cellular and Molecular Neuroscience and 2 papers in Epidemiology. Recurrent topics in Douglas Dolnak's work include Inflammatory mediators and NSAID effects (2 papers), Neuropeptides and Animal Physiology (2 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (1 paper). Douglas Dolnak is often cited by papers focused on Inflammatory mediators and NSAID effects (2 papers), Neuropeptides and Animal Physiology (2 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (1 paper). Douglas Dolnak collaborates with scholars based in United States. Douglas Dolnak's co-authors include Mark Hyman Rapaport, Stuart I. Brown, Rebecca Williams, Barbara L. Brody, Amanda R. Smith, Anthony Gamst, Robert M. Kaplan, Catherine Bresee, Rachel Maddux and Wei‐Guo Zhu and has published in prestigious journals such as Biological Psychiatry, Ophthalmology and The International Journal of Neuropsychopharmacology.

In The Last Decade

Douglas Dolnak

6 papers receiving 614 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas Dolnak United States	6	300	271	170	108	86	6	638
A. Orwin United Kingdom	12	58 0.2×	45 0.2×	78 0.5×	10 0.1×	82 1.0×	24	534
Philip Brenner Sweden	14	7 0.0×	27 0.1×	15 0.1×	179 1.7×	195 2.3×	27	664
Sanford R. Gifford United States	10	27 0.1×	22 0.1×	21 0.1×	9 0.1×	24 0.3×	22	405
Sedat Batmaz Türkiye	11	36 0.1×	14 0.1×	21 0.1×	43 0.4×	123 1.4×	51	382
Peixian Mao China	11	10 0.0×	23 0.1×	21 0.1×	29 0.3×	189 2.2×	22	421
Taha Amir Kuwait	8	5 0.0×	52 0.2×	22 0.1×	45 0.4×	245 2.8×	15	529
Sevda Korkmaz Türkiye	12	4 0.0×	20 0.1×	23 0.1×	30 0.3×	130 1.5×	75	505
V. Polin France	8	3 0.0×	54 0.2×	15 0.1×	22 0.2×	148 1.7×	10	604
Sibel Çakır Türkiye	14	9 0.0×	18 0.1×	15 0.1×	63 0.6×	433 5.0×	25	626
Anne M. Myhre Norway	14	5 0.0×	21 0.1×	16 0.1×	34 0.3×	220 2.6×	31	604

Countries citing papers authored by Douglas Dolnak

Since Specialization

Citations

This map shows the geographic impact of Douglas Dolnak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Dolnak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Dolnak more than expected).

Fields of papers citing papers by Douglas Dolnak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Dolnak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Dolnak. The network helps show where Douglas Dolnak may publish in the future.

Co-authorship network of co-authors of Douglas Dolnak

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Dolnak. A scholar is included among the top collaborators of Douglas Dolnak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Dolnak. Douglas Dolnak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Dolnak, Douglas. (2006). Treating patients for comorbid depression, anxiety disorders, and somatic illnesses.. PubMed. 106(5 Suppl 2). S1–8. 15 indexed citations

2.

Rapaport, Mark Hyman, et al.. (2005). Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia. Biological Psychiatry. 57(12). 1594–1596. 104 indexed citations

3.

Bresee, Catherine, et al.. (2005). The effects of celecoxib augmentation on cytokine levels in schizophrenia. The International Journal of Neuropsychopharmacology. 9(3). 343–343. 16 indexed citations

4.

Wang, Dunrui, et al.. (2003). Studies characterizing 60 kda autoantibodies in subjects with schizophrenia. Biological Psychiatry. 53(5). 361–375. 23 indexed citations

5.

Brody, Barbara L., Anthony Gamst, Rebecca Williams, et al.. (2001). Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 108(10). 1893–1900. 452 indexed citations

6.

Dolnak, Douglas, Clayton A. Wiley, Erik De Clercq, et al.. (1992). Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.. PubMed. 33(5). 1557–63. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact